Skip to main content

FDA committee says Achaogen failed to provide safety evidence

The Food and Drug Adminstration's Antimicrobial Drugs Advisory Committee voted 11 to 4 that Achaogen Inc. (Nasdaq: AKAO) failed to provide substantial evidence of safety and effectiveness of plazomicin to treat bloodstream infections. Shares of the biopharmaceutical plummeted $3.64 to close at $11.06.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.